{
    "nct_id": "NCT05451212",
    "official_title": "A Phase 1, Open-label, Safety and Dose-finding Study of Autologous Muscle-specific Tyrosine Kinase Chimeric Autoantibody Receptor T Cells (MuSK-CAART) in Subjects With Anti-MuSK-antibody-positive Myasthenia Gravis",
    "inclusion_criteria": "* Confirmed diagnosis of MuSK-type MG with at least 1 prior positive anti-MuSK antibody test.\n* History of a negative anti-AChR (acetylcholine receptor) antibody test.\n* Positive anti-MuSK antibody test at screening\n* MG severity Class I to IVa on the MGFA (Myasthenia Gravis Foundation of America) Clinical Classification\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Rituximab in the last 12 months.\n* Prednisone > 0.25mg/kg/day [in Part A]\n* Other autoimmune disorder requiring immunosuppressive therapies.\n* Investigational treatment for MG in the past 12 weeks.\n* Absolute lymphocyte count < 500/ÂµL at screening.",
    "miscellaneous_criteria": ""
}